arrow
E

Emma Culver

University of Oxford
H指数:34
被引数:4,309

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

PSC-DM: A Validated Clinical Diagnostic Model for Distinguishing Primary From Secondary Sclerosing Cholangitis

PSC-DM:一种区分原发性与继发性硬化性胆管炎的临床诊断模型

2026-10-010
OAAI
The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view

未经许可疗法在原发性胆汁性胆管炎中的伦理考量:一种对立观点

2026-02-190
PRE
Pruritus is common in primary sclerosing cholangitis, persists over time, and its intensity is associated with disease severity

瘙痒在原发性硬化性胆管炎中常见,会持续存在,其强度与疾病严重程度相关。

2025-12-010
PRE
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis

对奥贝胆酸的非应答与原发性胆汁性胆管炎患者发生临床事件的风险增加相关

2025-09-220
OAAI
Maintenance treatment for type 1 autoimmune pancreatitis: effectiveness and development of the PrescrAIP relapse prediction model

1型自身免疫性胰腺炎的维持治疗:疗效及PrescrAIP复发预测模型的发展

2025-09-130
PRE
Adherence to United European Gastroenterology Guidelines on Diagnosis and Therapy of Immunoglobulin-G4-Related Digestive Disease

对欧洲胃肠病学联盟关于IgG4相关消化系统疾病诊断和治疗指南的遵循

2025-07-220
OAAI
Fibrate-Oca (FI-OCA) Study-a Global snapshot of PBC practice around the Globe
2025-03-010
PRE
Noninvasive Assessment of Portal Hypertension in Patients With Primary Biliary Cholangitis Is Affected by Severity of Cholestasis

非侵入性评估原发性胆汁性胆管病患者的门静脉高压受胆汁淤积严重程度的影响

2024-12-130
OAAI
Type 1 Autoimmune Pancreatitis in Europe: Clinical Profile and Response to Treatment

欧洲的1型自身免疫性胰腺炎: 临床概况和对治疗的反应

2024-05-014
OAAI
Primary biliary cholangitis drug evaluation and regulatory approval: Where do we go from here?

原发性胆汁性胆管炎药物评估和监管批准: 我们从这里走向何方?

2024-03-226
OAAI